Satraplatin acts as a potent inhibitor of proliferation in castration-resistant prostate cancer, yet the basic and molecular pharmacological mechanisms are still unknown in all types of cancer including colorectal cancer (CRC). In an effort to explain the mechanism of tumour sensitivity to satraplatin, the cytotoxic effects in a panel of CRC cell lines was examined with regard to their p53 genotype in comparison with oxaliplatin.
Kalimutho, M., Minutolo, A., Grelli, S., Formosa, A., Sancesario, G., Valentini, A., et al. (2011). Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 67(6), 1299-1312 [10.1007/s00280-010-1428-4].
Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance
MINUTOLO, ANTONELLA;GRELLI, SANDRO;FEDERICI, GIORGIO;BERNARDINI, SERGIO
2011-06-01
Abstract
Satraplatin acts as a potent inhibitor of proliferation in castration-resistant prostate cancer, yet the basic and molecular pharmacological mechanisms are still unknown in all types of cancer including colorectal cancer (CRC). In an effort to explain the mechanism of tumour sensitivity to satraplatin, the cytotoxic effects in a panel of CRC cell lines was examined with regard to their p53 genotype in comparison with oxaliplatin.| File | Dimensione | Formato | |
|---|---|---|---|
|
n.4 Cancer Chemother Pharmacol 2011 grelli.pdf
accesso aperto
Licenza:
Copyright dell'editore
Dimensione
4.33 MB
Formato
Adobe PDF
|
4.33 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
